237 related articles for article (PubMed ID: 36478411)
21. Neoadjuvant Stereotactic Body Radiotherapy After Upfront Chemotherapy Improves Pathologic Outcomes Compared With Chemotherapy Alone for Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma Without Increasing Perioperative Toxicity.
Hill CS; Rosati LM; Hu C; Fu W; Sehgal S; Hacker-Prietz A; Wolfgang CL; Weiss MJ; Burkhart RA; Hruban RH; De Jesus-Acosta A; Le DT; Zheng L; Laheru DA; He J; Narang AK; Herman JM
Ann Surg Oncol; 2022 Apr; 29(4):2456-2468. PubMed ID: 35129721
[TBL] [Abstract][Full Text] [Related]
22. Study protocol for a prospective, open-label, single-arm, phase II study on the combination of tislelizumab, nab-paclitaxel, gemcitabine, and concurrent radiotherapy as the induction therapy for patients with locally advanced and borderline resectable pancreatic cancer.
Lu C; Zhu Y; Kong W; Yang J; Zhu L; Wang L; Tang M; Chen J; Li Q; He J; Li A; Qiu X; Gu Q; Chen D; Meng F; Liu B; Qiu Y; Du J
Front Oncol; 2022; 12():879661. PubMed ID: 36059628
[TBL] [Abstract][Full Text] [Related]
23. AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer.
Oar A; Lee M; Le H; Wilson K; Aiken C; Chantrill L; Simes J; Nguyen N; Barbour A; Samra J; Sjoquist KM; Moore A; Espinoza D; Gebski V; Yip S; Chu J; Kneebone A; Goldstein D
BMC Cancer; 2021 Aug; 21(1):936. PubMed ID: 34412605
[TBL] [Abstract][Full Text] [Related]
24. Intraoperative Radiation Therapy (IORT) for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (BR/LA PDAC) in the Era of Modern Neoadjuvant Treatment: Short-Term and Long-Term Outcomes.
Harrison JM; Wo JY; Ferrone CR; Horick NK; Keane FK; Qadan M; Lillemoe KD; Hong TS; Clark JW; Blaszkowsky LS; Allen JN; Castillo CF
Ann Surg Oncol; 2020 May; 27(5):1400-1406. PubMed ID: 31758284
[TBL] [Abstract][Full Text] [Related]
25. Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial.
Murphy JE; Wo JY; Ryan DP; Clark JW; Jiang W; Yeap BY; Drapek LC; Ly L; Baglini CV; Blaszkowsky LS; Ferrone CR; Parikh AR; Weekes CD; Nipp RD; Kwak EL; Allen JN; Corcoran RB; Ting DT; Faris JE; Zhu AX; Goyal L; Berger DL; Qadan M; Lillemoe KD; Talele N; Jain RK; DeLaney TF; Duda DG; Boucher Y; Fernández-Del Castillo C; Hong TS
JAMA Oncol; 2019 Jul; 5(7):1020-1027. PubMed ID: 31145418
[TBL] [Abstract][Full Text] [Related]
26. Neoadjuvant Phase II Trial of Chemoradiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer.
Thanikachalam K; Damarla V; Seixas T; Dobrosotskaya I; Wollner I; Kwon D; Winters K; Raoufi M; Li J; Siddiqui F; Khan G
Am J Clin Oncol; 2020 Jun; 43(6):435-441. PubMed ID: 32251119
[TBL] [Abstract][Full Text] [Related]
27. Intraoperative Radiotherapy in the Era of Intensive Neoadjuvant Chemotherapy and Chemoradiotherapy for Pancreatic Adenocarcinoma.
Keane FK; Wo JY; Ferrone CR; Clark JW; Blaszkowsky LS; Allen JN; Kwak EL; Ryan DP; Lillemoe KD; Fernandez-Del Castillo C; Hong TS
Am J Clin Oncol; 2018 Jun; 41(6):607-612. PubMed ID: 27740973
[TBL] [Abstract][Full Text] [Related]
28. Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm?
Christians KK; Tsai S; Mahmoud A; Ritch P; Thomas JP; Wiebe L; Kelly T; Erickson B; Wang H; Evans DB; George B
Oncologist; 2014 Mar; 19(3):266-74. PubMed ID: 24569947
[TBL] [Abstract][Full Text] [Related]
29. Dose escalated concurrent chemo-radiation in borderline resectable and locally advanced pancreatic cancers with tomotherapy based intensity modulated radiotherapy: a phase II study.
Lewis S; Sastri SC; Arya S; Mehta S; Patil P; Shrivastava S; Phurailatpam R; Shrikhande SV; Engineer R
J Gastrointest Oncol; 2019 Jun; 10(3):474-482. PubMed ID: 31183197
[TBL] [Abstract][Full Text] [Related]
30. Induction Chemotherapy With FOLFIRINOX Followed by Chemoradiation With Gemcitabine in Patients With Borderline-Resectable Pancreatic Ductal Adenocarcinoma.
Acuna-Villaorduna A; Shankar V; Wysota M; Jirgal A; Kabarriti R; Bellemare S; Goldman I; Kaubisch A; Aparo S; Goel S; Chuy J
Cancer Control; 2022; 29():10732748221134411. PubMed ID: 36221952
[TBL] [Abstract][Full Text] [Related]
31. Neoadjuvant therapy in elderly patients receiving FOLFIRINOX or gemcitabine/nab-paclitaxel for borderline resectable or locally advanced pancreatic cancer is feasible and lead to a similar oncological outcome compared to non-aged patients - Results of the RESPECT-Study.
Weniger M; Moir J; Damm M; Maggino L; Kordes M; Rosendahl J; Ceyhan GO; Schorn S;
Surg Oncol; 2020 Dec; 35():285-297. PubMed ID: 32949968
[TBL] [Abstract][Full Text] [Related]
32. Preoperative FOLFIRINOX for borderline resectable pancreatic cancer: Is radiation necessary in the modern era of chemotherapy?
Kim SS; Nakakura EK; Wang ZJ; Kim GE; Corvera CU; Harris HW; Kirkwood KS; Hirose R; Tempero MA; Ko AH
J Surg Oncol; 2016 Oct; 114(5):587-596. PubMed ID: 27444658
[TBL] [Abstract][Full Text] [Related]
33. Neoadjuvant
Peterson SL; Husnain M; Pollack T; Pimentel A; Loaiza-Bonilla A; Westendorf-Overley C; Ratermann K; Anthony L; Desimone P; Goel G; Kudrimoti M; Dineen S; Tzeng CD; Hosein PJ
Anticancer Res; 2018 Jul; 38(7):4035-4039. PubMed ID: 29970528
[TBL] [Abstract][Full Text] [Related]
34. A phase II study of gemcitabine/nab-paclitaxel/S-1 combination neoadjuvant chemotherapy for patients with borderline resectable pancreatic cancer with arterial contact.
Kondo N; Uemura K; Sudo T; Hashimoto Y; Sumiyoshi T; Okada K; Seo S; Otsuka H; Murakami Y; Takahashi S
Eur J Cancer; 2021 Dec; 159():215-223. PubMed ID: 34781169
[TBL] [Abstract][Full Text] [Related]
35. Induction gemcitabine and oxaliplatin therapy followed by a twice-weekly infusion of gemcitabine and concurrent external-beam radiation for neoadjuvant treatment of locally advanced pancreatic cancer: a single institutional experience.
Leone F; Gatti M; Massucco P; Colombi F; Sperti E; Campanella D; Regge D; Gabriele P; Capussotti L; Aglietta M
Cancer; 2013 Jan; 119(2):277-84. PubMed ID: 22778019
[TBL] [Abstract][Full Text] [Related]
36. Surgery Improves Survival After Neoadjuvant Therapy for Borderline and Locally Advanced Pancreatic Cancer: A Single Institution Experience.
Rangelova E; Wefer A; Persson S; Valente R; Tanaka K; Orsini N; Segersvärd R; Arnelo U; Del Chiaro M
Ann Surg; 2021 Mar; 273(3):579-586. PubMed ID: 30946073
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of neoadjuvant FOLFIRINOX versus gemcitabine plus nab-paclitaxel in borderline resectable/locally advanced pancreatic cancer patients.
Ingram MA; Lauren BN; Pumpalova Y; Park J; Lim F; Bates SE; Kastrinos F; Manji GA; Kong CY; Hur C
Cancer Rep (Hoboken); 2022 Sep; 5(9):e1565. PubMed ID: 35122419
[TBL] [Abstract][Full Text] [Related]
38. Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group.
Ettrich TJ; Berger AW; Perkhofer L; Daum S; König A; Dickhut A; Wittel U; Wille K; Geissler M; Algül H; Gallmeier E; Atzpodien J; Kornmann M; Muche R; Prasnikar N; Tannapfel A; Reinacher-Schick A; Uhl W; Seufferlein T
BMC Cancer; 2018 Dec; 18(1):1298. PubMed ID: 30594153
[TBL] [Abstract][Full Text] [Related]
39. Survival Outcomes Associated With Clinical and Pathological Response Following Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Chemotherapy in Resected Pancreatic Cancer.
Macedo FI; Ryon E; Maithel SK; Lee RM; Kooby DA; Fields RC; Hawkins WG; Williams G; Maduekwe U; Kim HJ; Ahmad SA; Patel SH; Abbott DE; Schwartz P; Weber SM; Scoggins CR; Martin RCG; Dudeja V; Franceschi D; Livingstone AS; Merchant NB
Ann Surg; 2019 Sep; 270(3):400-413. PubMed ID: 31283563
[TBL] [Abstract][Full Text] [Related]
40. CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma.
Wagner M; Antunes C; Pietrasz D; Cassinotto C; Zappa M; Sa Cunha A; Lucidarme O; Bachet JB
Eur Radiol; 2017 Jul; 27(7):3104-3116. PubMed ID: 27896469
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]